2. Academic Validation
  3. Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors

Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors

  • Eur J Med Chem. 2018 Jan 1:143:2005-2014. doi: 10.1016/j.ejmech.2017.11.021.
Raffaella Cincinelli 1,  Loana Musso 1,  Roberto Artali 2,  Mario Guglielmi 3,  Erminia Bianchino 3,  Francesco Cardile 3,  Fabiana Colelli 3,  Claudio Pisano 3,  Sabrina Dallavalle 4
Affiliations

Affiliations

  • 1 Department of Food, Environmental and Nutritional Sciences, Division of Chemistry and Molecular Biology, Università degli Studi di Milano, via Celoria 2, 20133 Milan, Italy.
  • 2 Scientia Advice, di Roberto Artali, 20832 Desio, MB, Italy.
  • 3 Biogem, Research Institute, Ariano Irpino, AV, Italy.
  • 4 Department of Food, Environmental and Nutritional Sciences, Division of Chemistry and Molecular Biology, Università degli Studi di Milano, via Celoria 2, 20133 Milan, Italy. Electronic address: sabrina.dallavalle@unimi.it.
PMID: 29150335 DOI: 10.1016/j.ejmech.2017.11.021
Abstract

Recent studies have demonstrated enhanced Anticancer effects of combination therapy consisting of camptothecin derivatives and HDAC inhibitors. To exploit this synergy in a single active compound, we designed new dual-acting multivalent molecules simultaneously targeting Topoisomerase I and HDAC. In particular, a selected compound containing a camptothecin and the psammaplin A scaffold showed a broad spectrum of antiproliferative activity, with IC50 values in the nanomolar range. Preliminary in vivo results indicated a strong antitumor activity on human mesothelioma primary cell line MM473 orthotopically xenografted in CD-1 nude mice and very high tolerability.

Keywords

Antiproliferative activity; Antitumor activity; Camptothecin; Dual-action inhibitors; HDAC inhibitors; Psammaplin.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z